Reverse transcription polymerase chain reaction (RT-PCR) analysis of PBMCs from MS patients revealed considerable systemic upregulation of CD40 and CD40L mRNAs as compared to healthy controls [185], but not at the protein level, with no difference across clinical MS subgroups or disease stage [186]. The gene discussed is CD40; the disease is myeloid sarcoma.